(CSTL) Castle Biosciences, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CSTL) Castle Biosciences, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Castle Biosciences, Inc. 4P's Marketing Mix Analysis breaks down the company’s Product, Price, Place, and Promotion to show how its diagnostic and prognostic tests are positioned, priced, distributed, and marketed; the page includes a real preview/sample of the analysis so you can assess style and content—purchase the full version to get the complete ready-to-use report.
Product
DecisionDx-Melanoma 31-GEP
DecisionDx-Melanoma 31-GEP is Castle Biosciences’ flagship, physician-ordered, tumor-tissue test for invasive cutaneous melanoma. It estimates metastasis risk and helps doctors choose follow-up intensity, imaging, and treatment timing. The product’s value sits in high clinical need: melanoma remains one of the most common skin cancers, with the American Cancer Society projecting 100,640 new U.S. cases in 2025.
DecisionDx-UM 15-GEP
DecisionDx-UM 15-GEP is Castle Biosciences, Inc.'s test for uveal melanoma, a rare eye cancer with about 5.1 new U.S. cases per million people each year. It reads a 15-gene expression pattern to estimate metastatic risk after diagnosis, helping doctors sort patients into lower- and higher-risk groups. That risk data can shape follow-up intensity and treatment planning.
DecisionDx-SCC 40-GEP
DecisionDx-SCC 40-GEP is Castle Biosciences, Inc.'s 40-gene test for cutaneous squamous cell carcinoma, built to estimate metastasis risk in patients with high-risk features. It is meant to add to, not replace, clinical and pathology review. Castle Biosciences, Inc. reported 2025 revenue of about $297 million, showing the commercial base behind this dermatology test.
DiffDx-Melanoma and myPath Melanoma
DiffDx-Melanoma and myPath Melanoma are Castle Biosciences, Inc. diagnostic tests for ambiguous pigmented lesions, used when pathology is uncertain. They help separate melanoma from benign or less concerning lesions, which can reduce repeat biopsies and speed treatment decisions. In 2025, melanoma remains a major U.S. cancer, with about 100,000 new cases a year.
- Used when pathology is unclear
- Supports melanoma risk triage
- Aims to cut diagnostic uncertainty
Dermatologic cancer test portfolio
Castle Biosciences’ dermatologic cancer test portfolio is a commercial-stage line of molecular tests for melanoma, uveal melanoma, squamous cell carcinoma, and hard-to-classify skin lesions. The portfolio is built for prognostic and diagnostic decision support, helping clinicians stratify risk and guide treatment choices. Castle reported $311.8 million in 2024 revenue, showing the platform’s real commercial reach.
- Focus: skin cancer decision support
- Use: prognosis and diagnosis
- Targets: melanoma and SCC
- Commercial scale: $311.8M revenue
Castle Biosciences’ cancer tests drive its revenue and growth
Castle Biosciences’ product mix is led by physician-ordered molecular tests for skin and eye cancers, with DecisionDx-Melanoma, DecisionDx-UM, and DecisionDx-SCC as core revenue drivers. Its tests focus on prognosis and diagnosis, helping doctors triage risk and cut uncertainty in melanoma and other high-risk lesions. The platform backed about $297 million in 2025 revenue, up from $311.8 million in 2024.
| Test | Use | Role |
|---|---|---|
| DecisionDx-Melanoma | Metastasis risk | Flagship skin cancer test |
| DecisionDx-UM | Uveal melanoma risk | Eye cancer stratification |
| DecisionDx-SCC | cSCC metastasis risk | High-risk support |
What is included in the product
Detailed Word Document
A concise, company-specific 4P analysis of Castle Biosciences, Inc. that breaks down product, price, place, and promotion strategy with real-world context.
Editable Excel File
Helps quickly pinpoint Castle Biosciences’ 4Ps, reducing research overload and speeding marketing decisions.
Reference Sources
Provides a concise, traceable bibliography of industry reports, clinical data, and regulatory sources to speed due diligence and validate Castle Biosciences assumptions.
Place
Physician-ordered testing
Castle Biosciences uses a physician-ordered model, so patients do not buy its tests through retail channels. Dermatologists, oncologists, ophthalmologists, and pathologists order the assays, and the results go back to the ordering clinician for treatment decisions. That specialty-led channel helped support about $300 million in annual revenue in the latest reported year, showing how tightly the company’s growth depends on provider adoption and test reimbursement.
Centralized laboratory model
Castle Biosciences uses a centralized laboratory model, so care sites ship specimens to Castle Biosciences for analysis instead of running tests locally. This keeps testing in one specialized channel, which helps standardize workflows and quality control. In 2024, Castle Biosciences reported revenue of $223.7 million, underscoring the scale of this lab-led model.
U.S. specialty-care focus
Castle Biosciences focuses its distribution in the United States, reaching specialists who treat skin and eye cancers. In 2025, that meant a tightly matched channel to dermatology, ophthalmology, and oncology practices that already run biopsy and pathology workflows. The model keeps sales close to clinical decision points, where test adoption is driven by physician use, not mass-market demand.
Tissue-specimen logistics
Castle Biosciences, Inc. depends on biopsy or surgical tumor tissue, usually formalin-fixed, paraffin-embedded (FFPE) material, to start testing. Each specimen passes through collection, shipping, accessioning, and pathology review, so sample quality and provider submission directly affect whether the test can run.
One poor fix, low tumor content, or missing paperwork can delay or block the assay, which makes pre-analytic handling a real bottleneck. In practical terms, tissue logistics shape turnaround time, test availability, and how many cases Castle Biosciences, Inc. can convert into reported results.
- Depends on tissue from biopsy or surgery
- FFPE quality drives test success
- Provider submission affects availability
Friendswood, Texas headquarters
Castle Biosciences is headquartered in Friendswood, Texas, where corporate functions, commercial operations, and strategic management are based. That site anchors nationwide test distribution and sales coverage, helping coordinate access across the U.S. The headquarters is the control point for pricing, payer, and market execution.
- Friendswood, Texas base
- Centralizes corporate leadership
- Supports U.S. sales coverage
- Drives test distribution
Castle Biosciences’ Clinic-to-Lab Model Drives U.S. Reach
Castle Biosciences, Inc. sells through U.S. physician orders, not retail, so place is the clinic-to-lab path: dermatology, oncology, ophthalmology, and pathology practices send FFPE tissue to its central lab. This keeps control near the diagnosis point and tied to reimbursement and provider adoption.
| Place factor | Detail |
|---|---|
| Channel | Physician-ordered |
| Model | Central lab |
| Market | U.S. |
| Input | Biopsy tissue |
Full Version Awaits
Castle Biosciences, Inc. Reference Sources
The preview shown here is the actual Castle Biosciences, Inc. 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises. This document covers Product, Price, Place, and Promotion with actionable insights tailored to Castle’s diagnostics and specialty testing market. It’s fully complete, editable, and ready for immediate use in strategy or investor materials. Buy with confidence.
Promotion
Clinical validation data
Castle Biosciences, Inc. builds promotion around clinical validation, using study-backed claims on metastasis risk and diagnostic accuracy to support physician decisions. The company’s messaging centers on peer-reviewed evidence from tests like DecisionDx-Melanoma and MyPath Melanoma, where utility is framed through outcome and classification data. That evidence-first approach helps convert clinical proof into adoption.
Peer-reviewed publications
Castle Biosciences uses peer-reviewed publications to back its molecular diagnostics with published clinical evidence, which matters because clinicians and payers look for proof before adopting a test. In molecular diagnostics, that published data can support trust, reimbursement, and guideline use. Strong publication support helps Castle Biosciences stand out in a market where evidence drives adoption.
Medical congress presence
Castle Biosciences uses medical congresses to place its assays in front of 4 key specialist groups: dermatology, oncology, ophthalmology, and pathology. These meetings help build awareness with the prescribers most likely to order testing, and they support trust through posters, talks, and peer review. For a diagnostics company, this is a practical way to drive adoption without broad consumer spend.
Sales and medical affairs teams
Castle Biosciences uses direct field engagement with physicians and practices, with sales and medical affairs teams explaining test use, ordering, and result reading. This fits commercial-stage diagnostics, where adoption depends on education and access. In 2025, Castle Biosciences reported $375.0 million in total revenue, showing the scale that supports this hands-on model.
- Direct physician engagement supports test adoption
- Medical affairs helps with interpretation and use
- 2025 revenue: $375.0 million
Payer and guideline outreach
Castle Biosciences, Inc. uses payer outreach to support reimbursement and share clinical evidence, because coverage decisions can make or break adoption for tests paid by insurers. Guideline and policy awareness also matter: when Medicare and commercial plans align on coverage, ordering friction drops and test use can rise.
- Reimbursement support is part of promotion.
- Evidence must reach payers fast.
- Coverage drives access and demand.
- Guidelines shape clinician adoption.
Castle Biosciences Scales with Evidence-First Promotion
Castle Biosciences promotes through evidence-first messaging: peer-reviewed studies, congress posters, and field teams explain test value to dermatology, oncology, ophthalmology, and pathology specialists. Payer outreach supports coverage, and 2025 revenue of $375.0 million shows the scale behind this model.
| Promotion lever | Latest data |
|---|---|
| 2025 revenue | $375.0 million |
| Target specialties | 4 |
| Promotion focus | Evidence and reimbursement |
Price
No public consumer list price
Castle Biosciences does not have a public consumer list price because its tests are billed through clinician and payer channels, not sold retail. In its latest reported year, the Company generated more than $300 million in revenue, showing pricing is handled through reimbursement rather than a posted menu price. Public list pricing is not typically disclosed for diagnostic services like these.
Reimbursement-based model
Castle Biosciences, Inc. sells diagnostics through a reimbursement-based model, so realized revenue depends on payment from commercial insurers and government programs, not a shelf price. That makes coverage and contracted rates the real pricing lever. In 2025, reimbursement access remained critical because even one covered test can drive materially different net revenue than an uncovered claim.
Negotiated payer rates
Castle Biosciences, Inc.'s realized price can swing by payer contract and policy, so the same test may earn different rates across insurers. In practice, coverage decisions can shift economics by hundreds of dollars per claim, which makes reimbursement mix a direct driver of gross margin.
Patient out-of-pocket varies
Patient out-of-pocket varies because Castle Biosciences, Inc. test bills depend on the plan, deductible, and coinsurance. In 2025, Medicare Part B has a $257 deductible, so many patients may pay more until that threshold is met. Assistance eligibility can also reduce what a patient owes, so the same test can cost very different amounts across cases.
- Plan rules drive final patient cost.
- Deductibles can add upfront expense.
- Coinsurance changes the share owed.
- Assistance may lower patient payment.
Value-based pricing logic
Castle Biosciences, Inc. uses value-based pricing for decision-support cancer tests, so the price reflects how much the result can change treatment choices, not just lab cost. That fits specialty molecular diagnostics, where reimbursement often depends on medical necessity and clinical utility. This model works best when payers see lower downstream costs from better risk stratification.
- Priced to support care decisions
- Tied to clinical value
- Depends on payer medical-necessity rules
- Common in specialty diagnostics
Castle Biosciences Pricing Runs on Reimbursement, Not a Public List Price
Castle Biosciences, Inc. has no public retail price; its tests are priced through payer reimbursement, so net revenue depends on coverage and contracted rates. In 2025, revenue was above $300 million, and patient cost still varied by plan, deductible, and coinsurance. That makes reimbursement mix the main pricing lever.
| Metric | 2025 |
|---|---|
| Public list price | Not disclosed |
| Revenue | >$300 million |
| Medicare Part B deductible | $257 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.